Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7763)
All Articles published online
|
Publishing Process of This Article
|
Dec 18, 2016 (publication date) through Dec 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol 2016; 8(35): 1557-1563 [PMID: 28050236 DOI: 10.4254/wjh.v8.i35.1557] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i35/1557.htm |
| Number | Citing Articles |
| 1 |
Silvia Goñi Esarte, Regina Juanbeltz, José Manuel Zozaya, Juan Isidro Úriz, Jesús Castilla, José Ignacio Herrero. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología 2020; 43(5): 248 doi: 10.1016/j.gastrohep.2019.03.017
|
| 2 |
Diego Casas-Deza, Ana Martínez-Sapiña, Silvia Espina, Beatriz Garcia-Rodriguez, Eva M. Fernandez-Bonilla, Alejandro Sanz-Paris, Yolanda Gonzalez-Irazabal, Vanesa Bernal-Monterde, Jose M. Arbones-Mainar. Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. Journal of Clinical Medicine 2022; 11(14): 4049 doi: 10.3390/jcm11144049
|
| 3 |
Marco SACCO, Giorgio M. SARACCO. The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. Minerva Gastroenterology 2021; 67(3) doi: 10.23736/S2724-5985.21.02835-X
|
| 4 |
Georgios Neokosmidis, Adonis A. Protopapas, Dimitrios Stogiannou, Athanasios Filippidis, Konstantinos Tziomalos. Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C. Gastroenterología y Hepatología 2023; 46(1): 58 doi: 10.1016/j.gastrohep.2022.03.007
|
| 5 |
Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Research 2022; 11: 649 doi: 10.12688/f1000research.109397.1
|
| 6 |
Silvia Goñi Esarte, Regina Juanbeltz, José Manuel Zozaya, Juan Isidro Úriz, Jesús Castilla, José Ignacio Herrero. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología (English Edition) 2020; 43(5): 248 doi: 10.1016/j.gastre.2019.03.027
|
| 7 |
Zabeer Bhatti, Jessica Norsworthy, Devamohan Sivalingam. Diabetes in a Hepatitis C and HIV-Coinfected Patient Treated With the Ledipasvir and Sofosbuvir Regimen. American Journal of Therapeutics 2018; 25(3): e391 doi: 10.1097/MJT.0000000000000572
|
| 8 |
Ines Bilić-Ćurčić, Hrvoje Roguljić, Marul Ivandić, Aleksandar Včev, Robert Smolić, Martina Smolić. Update on Hepatitis C. 2017; doi: 10.5772/intechopen.70721
|
| 9 |
Wesal Elgretli, Tianyan Chen, Nadine Kronfli, Giada Sebastiani. Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines 2023; 11(2): 271 doi: 10.3390/biomedicines11020271
|
| 10 |
Tatsuki Ichikawa, Hisamitsu Miyaaki, Satoshi Miuma, Yasuhide Motoyoshi, Syouhei Narita, Satomi Toda, Youichi Takahashi, Tetsurou Honda, Hiroyuki Yajima, Ryouhei Uehara, Naoyuki Hino, Tomoko Hori, Ryousuke Hirata, Naota Taura, Kazuhiko Nakao. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. Internal Medicine 2019; 58(9): 1209 doi: 10.2169/internalmedicine.1514-18
|
| 11 |
Daisuke Morihara, Yi‐Ling Ko, Kumiko Shibata, Ryo Yamauchi, Hiromi Fukuda, Naoaki Tsuchiya, Atsushi Fukunaga, Hideo Kunimoto, Hideyuki Iwashita, Kazuhide Takata, Takashi Tanaka, Kunitoshi Sakurai, Shinjiro Inomata, Keiji Yokoyama, Shinya Nishizawa, Yasuaki Takeyama, Makoto Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka. IL28B gene polymorphism is correlated with changes in low‐density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct‐acting antiviral treatment. Journal of Gastroenterology and Hepatology 2019; 34(11): 2019 doi: 10.1111/jgh.14741
|
| 12 |
Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/6150861
|
| 13 |
A. Olveira, L. Domínguez, J. Troya, A. Arias, F. Pulido, P. Ryan, L. M. Benítez, J. González‐García, M. L. Montes. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct‐acting antivirals. Journal of Viral Hepatitis 2018; 25(7): 818 doi: 10.1111/jvh.12883
|
| 14 |
Atsuyuki Ikeda, Kaori Ikeda, Atsushi Takai, Ken Takahashi, Yoshihide Ueda, Hiroyuki Marusawa, Horoshi Seno, Nobuya Inagaki, Hiroyuki Kokuryu. Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion 2017; 96(4): 228 doi: 10.1159/000484237
|
| 15 |
Abd Elkhalek Hamed, Medhat Elsahar, Nadia M. Elwan, Sarah El-Nakeep, Mervat Naguib, Hanan Hamed Soliman, Ashraf Ahmed Aboubakr, Amany AbdelMaqsod, Heba Sedrak, Samir N. Assaad, Reda Elwakil, Gamal Esmat, Samira Salh, Taymour Mostafa, Sherif Mogawer, Sameh Emil Sadek, Maha M. Saber, Hanan Ezelarab, Asem Ashraf Mahmoud, Souad Sultan, Mohamed El Kassas, Ehab Kamal, Naglaa M. ElSayed, Shorouk Moussa. Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). Arab Journal of Gastroenterology 2019; 20(1): 61 doi: 10.1016/j.ajg.2019.02.002
|
| 16 |
Anca Trifan, Tudor Cuciureanu, Robert Nastasa, Ermina Stratina, Sebastian Zenovia, Cristina Maria Muzica, Laura Huiban, Ana-Maria Singeap, Stefan Chiriac, Catalin Sfarti, Camelia Cojocariu, Irina Girleanu, Horia Minea, Remus Stafie, Adrian Rotaru, Carol Stanciu. Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection. Life 2023; 13(2): 534 doi: 10.3390/life13020534
|
| 17 |
Luigi Elio Adinolf, Ira Jacobson, Mark Bondin, Patrice Cacoub. Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus. Antiviral Therapy 2018; 23(1_suppl): 11 doi: 10.3851/IMP3255
|
| 18 |
Abd Elkhalek Hamed, Medhat Elsahar, Nadia M. Elwan, Sarah El-Nakeep, Mervat Naguib, Hanan Hamed Soliman, Ashraf Ahmed Aboubakr, Amany AbdelMaqsod, Heba Sedrak, Samir N. Assaad, Reda Elwakil, Gamal Esmat, Samira Salh, Taymour Mostafa, Sherif Mogawer, Sameh Emil Sadek, Maha M. Saber, Hanan Ezelarab, Asem Ashraf Mahmoud, Souad Sultan, Mohamed El Kassas, Ehab Kamal, Naglaa M. ElSayed, Shorouk moussa. Managing diabetes and liver disease association. Arab Journal of Gastroenterology 2018; 19(4): 166 doi: 10.1016/j.ajg.2018.08.003
|
| 19 |
Luigi Elio Adinolfi, Luca Rinaldi, Aldo Marrone, Mauro Giordano. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. Expert Review of Anti-infective Therapy 2018; 16(8): 595 doi: 10.1080/14787210.2018.1505500
|
| 20 |
Kamolyut Lapumnuaypol, David Pisarcik, Prapaipan Putthapiban, Weera Sukhumthammarat, Karn Wijarnpreecha, Charat Thongprayoon, Patompong Ungprasert. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus. Indian Journal of Medical Research 2020; 152(6): 562 doi: 10.4103/ijmr.IJMR_1088_18
|
| 21 |
Joana Rita Carvalho, José Velosa, Fátima Serejo. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication – comparison of the new direct-acting antiviral agents with the old regimens. Scandinavian Journal of Gastroenterology 2018; 53(7): 857 doi: 10.1080/00365521.2018.1473486
|
| 22 |
Pin-Nan Cheng, Yen-Cheng Chiu, Shih-Chieh Chien, Hung-Chih Chiu. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Journal of the Formosan Medical Association 2019; 118(5): 907 doi: 10.1016/j.jfma.2018.09.016
|
| 23 |
Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Darrag, Hassan Zied, Mohamed Sabry Aboelnasr. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022; : 1261 doi: 10.2147/DMSO.S354023
|
| 24 |
Shereen Abdel Alem, Aisha Elsharkawy, Rabab Fouad, Eman Adel, Zeinab Abdellatif, Sherief Musa, Ahmed Nagy, Muhammad S. Hussein, Ayman Yosry, Gamal Esmat. Improvement of glycemic state among responders to Sofosbuvir‐based treatment regimens: Single center experience. Journal of Medical Virology 2017; 89(12): 2181 doi: 10.1002/jmv.24897
|
| 25 |
Pradeep Kumar Mada, Matthew E. Malus, Arvin Parvathaneni, Bing Chen, Gabriel Castano, Sharon Adley, Maureen Moore, Michinari Hieda, Mohammed J. Alam, Mark Feldman, John William King. Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus. International Journal of Hepatology 2020; 2020: 1 doi: 10.1155/2020/6438753
|
| 26 |
Z A Kalmykova, I V Kononenko, A Yu Mayorov. Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features. Terapevticheskii arkhiv 2019; 91(12): 115 doi: 10.26442/00403660.2019.12.000166
|
| 27 |
Naoyuki Hino, Ryu Sasaki, Youichi Takahashi, Makiko Koike, Masanori Fukushima, Masafumi Haraguchi, Takuya Honda, Satoshi Miuma, Eisuke Ozawa, Hisamitsu Miyaaki, Tatsuki Ichikawa, Kazuhiko Nakao. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Internal Medicine 2021; 60(2): 191 doi: 10.2169/internalmedicine.5563-20
|
| 28 |
Jucéli Márcia Hendges Sparvoli, Antonio Cardoso Sparvoli, Afonso Alexandre Pereira, Ana Luisa Machado de Paula, Laís Garcia, Carla Vitola Gonçalves. Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals. Revista da Associação Médica Brasileira 2023; 69(5) doi: 10.1590/1806-9282.20221163
|
| 29 |
Tatsuo Kanda, Mitsuhiko Moriyama. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World Journal of Gastroenterology 2017; 23(31): 5645-5649 doi: 10.3748/wjg.v23.i31.5645
|
| 30 |
Vanessa Gutierrez de ANDRADE, Fabio da Silva YAMASHIRO, Cassio Vieira OLIVEIRA, Leticia Lastória KUROZAWA, Alecsandro MOREIRA, Giovanni Faria SILVA. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?. Arquivos de Gastroenterologia 2018; 55(2): 184 doi: 10.1590/s0004-2803.201800000-33
|
| 31 |
Simone Lanini, Paola Scognamiglio, Raffaella Pisapia, Claudia Minosse, Alessandro Agresta, Giuseppe Ippolito. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. International Journal of Antimicrobial Agents 2019; 53(5): 559 doi: 10.1016/j.ijantimicag.2018.11.024
|
| 32 |
Noriyuki Akutsu, Shigeru Sasaki, Takeshi Matsui, Hirofumi Akashi, Kazuhiko Yonezawa, Keisuke Ishigami, Masayuki Tsujisaki, Hiroyuki Isshiki, Atsushi Yawata, Satoshi Yamaoka, Toshihiro Ban, Takeya Adachi, Seiya Nakahara, Hideyasu Takagi, Kohei Nakachi, Katsunori Tanaka, Takehiro Hirano, Itaru Yamamoto, Hiroyuki Kaneto, Kohei Wagatsuma, Yasunao Numata, Hiroshi Nakase. Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment. Internal Medicine 2021; 60(21): 3369 doi: 10.2169/internalmedicine.7098-21
|
| 33 |
Coline Seurre, Armando Andres Roca Suarez, Barbara Testoni, Fabien Zoulim, Boyan Grigorov. After the Storm: Persistent Molecular Alterations Following HCV Cure. International Journal of Molecular Sciences 2024; 25(13): 7073 doi: 10.3390/ijms25137073
|
| 34 |
Liana Gheorghe, Speranta Iacob. Essentials of Non-Alcoholic Fatty Liver Disease. 2023; : 133 doi: 10.1007/978-3-031-33548-8_12
|
| 35 |
Ahmed Samir Allam, Mohamed Lotfy Abd Elmeged, Sameh Mohamed Ghaly, Osama Ashraf Ahmed, Gina Gamal Naguib, Ahmed Samir Abohalima. Impact of direct-acting antiviral therapy on metabolic profiles and adiponectin serum level in different categories of patients with chronic hepatitis C infection. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00194-z
|
| 36 |
Jia Li. Letter: HCV complication and type 2 diabetes management—the directional link is not yet defined. Authors’ reply. Alimentary Pharmacology & Therapeutics 2019; 49(9): 1251 doi: 10.1111/apt.15247
|
| 37 |
Evangelista Sagnelli, Caterina Sagnelli, Antonio Russo, Mariantonietta Pisaturo, Clarissa Camaioni, Roberta Astorri, Nicola Coppola. Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology 2020; 1323: 115 doi: 10.1007/5584_2020_604
|
| 38 |
Martina Spaziante, Gloria Taliani, Giulia Marchetti, Alessandro Tavelli, Miriam Lichtner, Antonella Cingolani, Stefania Cicalini, Elisa Biliotti, Enrico Girardi, Andrea Antinori, Massimo Puoti, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021; 13(7): 1402 doi: 10.3390/v13071402
|
| 39 |
Jia Li, Stuart C. Gordon, Loralee B. Rupp, Talan Zhang, Sheri Trudeau, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Mark A. Schmidt, Yihe G. Daida, Mei Lu. Sustained virological response does not improve long‐term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver International 2019; 39(6): 1027 doi: 10.1111/liv.14031
|
| 40 |
Anna Maria Spera, Pasquale Pagliano, Valeria Conti. Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?. World Journal of Hepatology 2024; 16(5): 661-666 doi: 10.4254/wjh.v16.i5.661
|
| 41 |
Takumi Kawaguchi, Hironori Koga, Takuji Torimura. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Current Hepatology Reports 2017; 16(4): 317 doi: 10.1007/s11901-017-0370-x
|
| 42 |
Mary-Anne Doyle, Chrissi Galanakis, Erin Mulvihill, Angela Crawley, Curtis L. Cooper. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. Cells 2019; 8(3): 252 doi: 10.3390/cells8030252
|
| 43 |
Davide Giuseppe Ribaldone, Marco Sacco, Giorgio Maria Saracco. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. Journal of Clinical Medicine 2020; 9(2): 563 doi: 10.3390/jcm9020563
|
| 44 |
Georgios Neokosmidis, Adonis A. Protopapas, Dimitrios Stogiannou, Athanasios Filippidis, Konstantinos Tziomalos. Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C. Gastroenterología y Hepatología (English Edition) 2023; 46(1): 58 doi: 10.1016/j.gastre.2022.03.008
|